Geron Balance Sheet Health
Financial Health criteria checks 4/6
Geron has a total shareholder equity of $259.5M and total debt of $119.0M, which brings its debt-to-equity ratio to 45.8%. Its total assets and total liabilities are $555.2M and $295.7M respectively.
Key information
45.85%
Debt to equity ratio
US$118.99m
Debt
| Interest coverage ratio | n/a |
| Cash | US$387.98m |
| Equity | US$259.53m |
| Total liabilities | US$295.67m |
| Total assets | US$555.20m |
Recent financial health updates
Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money
Aug 07
Is Geron (NASDAQ:GERN) A Risky Investment?
Apr 17We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Recent updates
Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money
Aug 07Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up
Jun 13Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)
Jun 11Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results
May 10
EU Approval And US Initiatives Will Expand Future Markets
European expansion with RYTELO's approval and launch could significantly boost revenue through international growth and increased market reach.Is Geron (NASDAQ:GERN) A Risky Investment?
Apr 17Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments
Mar 31Geron Corp: How Concerned Should We Be About Rytelo Sales?
Mar 17Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%
Mar 12We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Feb 26Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Feb 03Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Financial Position Analysis
Short Term Liabilities: GERN's short term assets ($505.6M) exceed its short term liabilities ($64.3M).
Long Term Liabilities: GERN's short term assets ($505.6M) exceed its long term liabilities ($231.4M).
Debt to Equity History and Analysis
Debt Level: GERN has more cash than its total debt.
Reducing Debt: GERN's debt to equity ratio has increased from 0% to 45.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GERN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GERN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/17 01:33 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Geron Corporation is covered by 28 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Peter Lawson | Barclays |
| George Zavoico | B. Riley Securities, Inc. |